Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-23 00:00:00 ET · period of report 2024-02-21 · accession 0000875320-24-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-23 | 2024-02-21 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $421.77 | -1,201 | 18.5K | -6% | -$506.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-21 | S | D | 1,201 | $421.77 | 18,509 | D | — | — |